Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 8,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Light-deprivation Utilized to Mitigate Amblyopia

NCT02685423
View directory record Official record
Conditions
Amblyopia
Interventions
Binocular deprivation 10 days, Vision training
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 31, 2026, 1:44 AM EDT
Completed No phase listed Observational Results available

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

NCT06086340
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib, Aromatase Inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 31, 2026, 1:44 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Conversational AI for Adult Flu Vaccination Decisions

NCT07896850
View directory record Official record
Conditions
Influenza, Human, Vaccine Hesitancy
Interventions
Flu vaccination guide, Accident safety guide
Behavioral
Lead sponsor
Calypta Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Early Phase 1 Interventional

Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness

NCT02311374
View directory record Official record
Conditions
Brain Mapping
Interventions
Brain connectivity and physiology, Brain Wave
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Results available

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

NCT01012323
View directory record Official record
Conditions
Primary Immunodeficiency Diseases
Interventions
NewGam
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Irvine, California • Centennial, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional

The Safety of ahSC in Chronic SCI With Rehabilitation

NCT02354625
View directory record Official record
Conditions
Spinal Cord Injury, Paraplegia, Quadriplegia, Tetraplegia
Interventions
Autologous human Schwann cells
Biological
Lead sponsor
W. Dalton Dietrich
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 31, 2026, 1:44 AM EDT
Recruiting Not applicable Interventional

Effect of Prenatal and Postnatal Intervention Strategies on Breastfeeding Outcomes in Women With Excessive Weight (Ready, Set, Nourish Study)

NCT06929091
View directory record Official record
Conditions
Breastfeeding, Dietary Intervention, Milk Expression, Breast
Interventions
Lactation Support and ABME, Lactation Support and meal plan, Lactation Support
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Recruiting Phase 2 Interventional

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

NCT07601074
View directory record Official record
Conditions
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Interventions
Lopinavir / ritonavir
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
22 Years to 50 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 2 Interventional

Tidal Lavage in Knee Osteoarthritis

NCT00000424
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Tidal lavage vs. sham lavage of the knee
Procedure
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
40 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 1, 2007 · Synced Oct 31, 2026, 1:44 AM EDT
Terminated Phase 2 Interventional

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

NCT06032546
View directory record Official record
Conditions
Human Immuno-deficiency Virus (HIV) Disease
Interventions
Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Not applicable Interventional

Cholesterol and Statin in Healthy Adults

NCT02908425
View directory record Official record
Conditions
Elevated HMB Excretion
Interventions
Statin user
Other
Lead sponsor
Texas A&M University
Other
Eligibility
65 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 31, 2026, 1:44 AM EDT
Active, not recruiting Not applicable Interventional Results available

Fetoscopic NEOX Cord 1K® Spina Bifida Repair

NCT04243889
View directory record Official record
Conditions
Spina Bifida, Myelomeningocele, Myeloschisis
Interventions
NEOX Cord 1K
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

NCT02452268
View directory record Official record
Conditions
Metastatic and Advanced Solid Tumors
Interventions
NIZ985, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Bethesda, Maryland • St Louis, Missouri • Columbus, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 31, 2026, 1:44 AM EDT
Recruiting Phase 4 Interventional

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

NCT06598397
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Smoking Cessation
Interventions
Motivational Interviewing (MI) Counseling, Peer Mentoring, Skills-based Text Messaging, Combination NRT
Behavioral · Drug
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07063823
View directory record Official record
Conditions
Celiac Disease, Healthy
Interventions
HB-2121
Drug
Lead sponsor
Nielsen Fernandez-Becker
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

NCT02124161
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions
13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes

NCT04880291
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases
Interventions
GFB-024, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Nursing Involvement on Implementation of HIV Prevention Services

NCT05095818
View directory record Official record
Conditions
Pre-Exposure Prophylaxis (PrEP)
Interventions
PrEP-RN
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

NCT03005782
View directory record Official record
Conditions
Malignancies
Interventions
REGN3767, cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
33
States / cities
Encinitas, California • Fresno, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

NCT01568203
View directory record Official record
Conditions
Schizophrenia
Interventions
AMG 579, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 31, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

NCT02218125
View directory record Official record
Conditions
Healthy
Interventions
MVA Mosaic, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 31, 2026, 1:44 AM EDT